Brief: Alligator Bioscience Receives Waiver For Paediatric Trials Of Mitazalimab
20/05/2025 13:32
May 20 (Reuters) - Alligator Bioscience AB ATORX.ST: EMA GRANTS WAIVER FOR PAEDIATRIC TRIALS OF MITAZALIMAB WAIVER REMOVES A KEY REQUIREMENT AHEAD OF POTENTIAL FUTURE MARKETING AUTHORIZATION SUBMISSIONS IN THE EUROPEAN UNION Source text: ID:nMFNbgt6sR Further company coverage: ATORX.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Alligator Bioscience AB
See all newsBrief: Alligator Bioscience Q1 Net Loss SEK 1.4 Million
Sweden's Alligator Bioscience posts Q1 net profit, narrows operating loss
Brief: Alligator Bioscience Q1 EBIT SEK -17.8 Million
Brief: Alligator Bioscience Signs LoI With Unicancer For Phase 3 Mitazalimab Development
Brief: Exercise Of Warrants Brings Alligator Bioscience Net Proceeds Of SEK 12 Mln